HMGCS1 Antibody [D13C18]

Catalog No.: F5434

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:30
    1:100
    Application
    WB, IP, IHC
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse, Rat
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    57 kDa 57 kDa,36 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    HMGCS1 Antibody [D13C18] detects endogenous levels of total HMGCS1 protein.
    Clone
    D13C18
    Synonym(s)
    HMGCS, HMGCS1, HMG-CoA synthase, 3-hydroxy-3-methylglutaryl coenzyme A synthase
    Background
    3-Hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) is the cytosolic isoform of HMG-CoA synthase and acts as the first committed enzyme of the mevalonate branch of cholesterol biosynthesis, catalyzing the condensation of acetyl-CoA with acetoacetyl-CoA to generate HMG-CoA that feeds directly into HMG-CoA reductase and the downstream production of sterols and non‑sterol isoprenoids. The enzyme belongs to the thiolase superfamily and functions as a homodimeric cytosolic protein with a catalytic site that positions acetyl-CoA and acetoacetyl-CoA for Claisen condensation, providing a gatekeeping step that determines the flux of acetyl units from central carbon metabolism into the mevalonate pathway. HMGCS1 activity links acetyl-CoA availability to the synthesis of mevalonate-derived products such as cholesterol, dolichols, ubiquinone, and prenyl donors, and thereby influences membrane biogenesis, protein prenylation, and other lipid‑dependent processes that support cell growth and survival. Expression of HMGCS1 is detectable in many tissues and aligns with sites of active cholesterol synthesis, and transcriptional control integrates with sterol regulatory networks that coordinate HMGCS1 with HMG-CoA reductase and other mevalonate enzymes to maintain intracellular sterol homeostasis. Elevated HMGCS1 expression is a recurrent feature of tumor cells with heightened mevalonate pathway activity, where increased HMGCS1 levels correlate with aggressive phenotypes and provide a metabolic signature of cancer stem cell–enriched subpopulations in luminal and basal breast cancer models, associating this enzyme with self‑renewal capacity and resistance‑related traits. Functional targeting of HMGCS1 in these breast cancer models diminishes cancer stem cell markers, sphere‑forming capacity, and tumorigenic features more strongly than standard statin treatment and acts at the level of HMG-CoA generation upstream of HMG-CoA reductase. In gastric cancer, HMGCS1 expression aligns with tumor progression, and pathway analyses place this enzyme as a regulatory node whose activity supports proliferation, migration, and other malignant properties through sustained provision of mevalonate intermediates required for oncogenic signaling and membrane dynamics.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください